Related references
Note: Only part of the references are listed.MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis
Praneil Patel et al.
NEURO-ONCOLOGY (2017)
Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI
S. Wang et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2016)
Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?
Rovel J. Colaco et al.
JOURNAL OF NEUROSURGERY (2016)
Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence
A. J. Prager et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2015)
T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status
J. Arevalo-Perez et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2015)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma
Alissa A. Thomas et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Hideho Okada et al.
LANCET ONCOLOGY (2015)
Response assessment criteria for brain metastases: proposal from the RANO group
Nancy U. Lin et al.
LANCET ONCOLOGY (2015)
Glioma: Application of Histogram Analysis of Pharmacokinetic Parameters from T1-Weighted Dynamic Contrast-Enhanced MR Imaging to Tumor Grading
S. C. Jung et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2014)
MRI perfusion in determining pseudoprogression in patients with glioblastoma
Robert J. Young et al.
CLINICAL IMAGING (2013)
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The treatment of brain metastases in melanoma patients
D Bafaloukos et al.
CANCER TREATMENT REVIEWS (2004)
Share Paper
